Yes, ImmunityBio shareholders should strongly consider joining the securities class action lawsuit against the company. If you purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 25, 2026, you are likely eligible to participate in the ongoing litigation brought by Robbins LLP and Rosen Law Firm.
The class action alleges that ImmunityBio and its leadership made materially misleading statements about Anktiva, the company’s bladder cancer treatment, causing investors to suffer substantial losses when the FDA issued a warning letter on March 24, 2026 that exposed these exaggerations. This article explains what happened with ImmunityBio’s stock, why the company faces securities fraud allegations, and what shareholders need to know about joining the class action lawsuit. We’ll cover the FDA’s specific allegations, the financial impact on investors, important deadlines you need to meet, and the practical steps required to participate in the lawsuit or claim compensation.
Table of Contents
- What Triggered the ImmunityBio Securities Class Action Lawsuit?
- Understanding the FDA Warning Letter and Its Implications
- The Financial Impact on ImmunityBio Investors
- Important Deadlines and How to Protect Your Rights
- How to Evaluate and Select Securities Class Action Counsel
- The Role of Insurance and Settlement Prospects
- Looking Forward—What to Watch in the ImmunityBio Case
What Triggered the ImmunityBio Securities Class Action Lawsuit?
On March 24, 2026, the FDA issued a warning letter to ImmunityBio that revealed the company had made misleading promotional communications about Anktiva, claiming the treatment could “cure and even prevent all cancer.” These exaggerated claims went far beyond what the clinical evidence supported, and the FDA’s letter exposed what the company had been promoting to the market. The same day this warning became public, ImmunityBio’s stock price collapsed, dropping $1.98 per share (approximately 21%) to close at $7.42, directly demonstrating how the market responded once investors learned the truth about the company’s earlier statements. The securities class action alleges that defendant Soon-Shiong, through the company’s promotional communications and statements during the class period from January 19, 2026 to March 25, 2026, deliberately or recklessly overstated Anktiva’s capabilities and therapeutic potential. Investors who purchased shares during this period relied on these misrepresentations and suffered losses when the FDA warning letter revealed the actual state of affairs.
The complaint argues this constitutes securities fraud under federal law, making shareholders eligible for compensation. This type of securities class action is common when senior company officials make materially false statements that artificially inflate stock prices, then a “trigger event”—in this case, an FDA warning letter—exposes the deception and causes the stock to plummet. Investors who bought at the inflated prices lose money, while those who sold beforehand avoid the losses. The law recognizes this asymmetry and allows class actions to recover damages on behalf of defrauded shareholders.
Understanding the FDA Warning Letter and Its Implications
The FDA warning letter is not a minor regulatory slap on the wrist—it’s a serious enforcement action that formally documents the company’s violations. The FDA specifically alleged that immunitybio‘s promotional communications created a false and misleading impression about Anktiva’s clinical utility and benefits. By claiming the drug could “cure and even prevent all cancer,” the company made claims that exceed anything supported by clinical trial data or scientific evidence for a bladder cancer treatment. This distinction matters because it shows the FDA found intentional or at least reckless exaggeration, not simple honest disagreement about how to characterize the drug’s benefits.
For shareholders, the warning letter has several practical consequences beyond the immediate stock price drop. First, it signals that regulatory approval or further development of Anktiva may face significant headwinds, as the FDA has now formally documented its concerns about the company’s credibility and the truthfulness of its claims. Second, it creates legal liability for the company and its executives for having made false statements to investors and the public. Third, it damages the company’s reputation with healthcare providers, patients, and investors—trust that is extremely difficult to rebuild in the pharmaceutical industry. However, if ImmunityBio responds to the FDA’s concerns by revising its marketing materials, conducting additional clinical trials, or submitting a formal response to the warning letter, there could potentially be a path forward, though it would likely take considerable time and expense.
The Financial Impact on ImmunityBio Investors
The 21% stock price decline on March 24, 2026 represents a significant but not unusual market reaction to negative news in the biotech sector. If you purchased 1,000 shares at an average price of $9.40 during the class period, your investment of $9,400 would be worth approximately $7,420 at the post-FDA-letter price, resulting in a loss of $1,980 on that position alone. For larger investors or those who purchased at prices near the peak of the class period, the losses can be substantially greater. These are real dollars lost by real people—retirement accounts, college savings plans, and investment portfolios that were supposed to grow but instead shrank overnight.
The stock price decline also reveals what financial analysts and the market believed about the true value of ImmunityBio’s core assets once the FDA’s concerns became public. Before March 24, 2026, the market was pricing in optimism about Anktiva’s commercial potential based on the company’s promotional statements. After the warning letter, the market repriced the stock based on the reality that Anktiva’s claims were exaggerated and its regulatory path was now uncertain. This repricing is precisely what the securities class action uses to calculate damages—the difference between what shareholders paid during the fraud period and what the stock was worth once the truth emerged.
Important Deadlines and How to Protect Your Rights
The lead plaintiff deadline for the ImmunityBio class action is May 26, 2026, which means you must file a motion with the court if you want to be considered as a lead plaintiff who will represent the class. This deadline is strict and courts typically do not extend it, so if you hold significant losses from ImmunityBio shares and want to have a leadership role in the lawsuit, you need to act immediately. Most individual shareholders, however, do not become lead plaintiffs—instead, they participate in the class action as regular class members without taking any active role.
For regular class members, there are typically looser deadlines, but they depend on whether you receive direct notice of the lawsuit. If you purchased ImmunityBio shares through a brokerage account, you may eventually receive a notice and claim form in the mail or email, which will have its own deadline (typically several months away from the settlement, if one is reached). However, the prudent approach is to consult with a securities attorney now rather than waiting to see if notice finds you. An attorney can advise you on whether you have a viable claim, how much compensation you might recover, and whether you should file early rather than relying on notice that may arrive late or get lost.
How to Evaluate and Select Securities Class Action Counsel
Not all securities attorneys are equal, and selecting the right one matters for your recovery. Robbins LLP and Rosen Law Firm are the two major firms that have filed securities class actions against ImmunityBio so far, and both have track records in securities litigation. However, you are not locked into any particular firm just because you received a solicitation—you can choose to work with any qualified securities attorney, or you can wait to see if one firm is designated as lead counsel by the court and then participate through them.
When evaluating a securities attorney, look for experience specifically in securities class actions, a verifiable track record of recovering money for clients, transparent fee structures (securities class actions typically work on a contingency basis, meaning the attorney only gets paid if there is a recovery), and clear communication about what your actual damages might be. Be wary of any attorney who guarantees a specific outcome or recovery amount—securities litigation is uncertain and settlements depend on many factors, including the defendant’s insurance coverage, the strength of the evidence, and the judge’s assessment of the case. One limitation to understand: even if you win the case or receive a settlement, the recovery may be considerably less than your total losses, as the settlement fund is typically divided among thousands of shareholders and the attorneys receive a percentage for their work.
The Role of Insurance and Settlement Prospects
ImmunityBio’s ability to pay a settlement will depend heavily on whether it has directors and officers liability insurance, which is common among public companies. If the company is insured, the insurance policy will likely cover a significant portion of any settlement, meaning shareholders could recover money even if ImmunityBio itself lacks sufficient assets. Without insurance, recovery prospects diminish considerably, as the company’s liquid assets become the only available source of compensation.
This is an important practical question to ask your attorney early on—do you know if ImmunityBio has D&O insurance, and if so, what are the policy limits? Settlement in securities class actions typically occurs 18 to 36 months after the complaint is filed, though timelines vary widely. Some cases settle quickly if the evidence is strong and the company wants to avoid a protracted trial, while others drag on for years. The eventual settlement amount depends on negotiations between the plaintiffs’ attorneys and the defendants’ insurance carriers, and these negotiations are heavily influenced by what a jury might award if the case went to trial. For ImmunityBio specifically, the strength of the evidence about what the company knew regarding Anktiva’s actual capabilities at the time it made its statements will be crucial in determining settlement value.
Looking Forward—What to Watch in the ImmunityBio Case
The coming weeks and months will be critical for the ImmunityBio securities litigation. Courts will determine whether Robbins LLP, Rosen Law Firm, or another firm is designated as lead counsel, and lead counsel will take the helm in pursuing discovery—the process of obtaining documents and testimony from ImmunityBio and its executives. The discovery process will either strengthen or weaken the plaintiffs’ case depending on what internal documents reveal about what company leadership knew regarding Anktiva’s actual clinical profile and whether executives made conscious choices to overstate the drug’s benefits.
Additionally, watch for developments regarding whether the FDA’s warning letter leads to more serious regulatory action, such as suspension of investigational new drug applications or restrictions on Anktiva’s development. Regulatory setbacks beyond the warning letter could increase ImmunityBio’s liability and settlement exposure, while regulatory improvements or company responses that satisfy the FDA’s concerns could reduce it. Shareholders participating in the class action should expect the case to evolve significantly over the next 12-24 months before any settlement becomes likely.
You Might Also Like
- ImmunityBio Securities Class Action Deadline Set for May 26 2026
- ImmunityBio Investors Targeted in New Securities Class Action Filing
- ImmunityBio Faces Another Securities Fraud Class Action on Behalf of Investors
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: